Parathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108782
Title:
Parathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia.
Authors:
Dodwell, David J; Abbas, S K; Morton, A R; Howell, Anthony ( 0000-0002-6233-719X )
Abstract:
A region-specific radioimmunoassay has been employed to measure levels of immunoreactive parathyroid hormone-related protein(50-69) (iPTHrP(50-69)) in patients with tumour-induced hypercalcaemia (TIH). This assay is based on an antiserum raised against synthetic human PTHrP(50-69). The assay showed no cross-reactivity with human or bovine parathyroid hormone(1-84). The effect of a single dose (60 mg) of pamidronate was studied in 25 consecutive patients with TIH. All were rehydrated prior to treatment. All but 2 patients (8%) became normocalcaemic after treatment; both of these had very high levels of iPTHrP(50-69). Time to achieve normocalcaemia, as an index of relative resistance to pamidronate, correlated positively with pretreatment level of iPTHrP(50-69). Absence of radiological evidence of bone metastases also predicted relative resistance to pamidronate. In this study, iPTHrP(50-69)-induced osteoclastic bone resorption was a more important mechanism in the causation of TIH than PTHrP-induced renal reabsorption of calcium as assessed by the renal thresholds for calcium and phosphate.
Affiliation:
Department of Medical Oncology, Christie Hospital, Manchester, U.K.
Citation:
Parathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia. 1991, 27 (12):1629-33 Eur. J. Cancer
Journal:
European Journal of Cancer
Issue Date:
1991
URI:
http://hdl.handle.net/10541/108782
PubMed ID:
1782072
Type:
Article
Language:
en
ISSN:
0959-8049
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorDodwell, David Jen
dc.contributor.authorAbbas, S Ken
dc.contributor.authorMorton, A Ren
dc.contributor.authorHowell, Anthonyen
dc.date.accessioned2010-08-02T10:15:42Z-
dc.date.available2010-08-02T10:15:42Z-
dc.date.issued1991-
dc.identifier.citationParathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia. 1991, 27 (12):1629-33 Eur. J. Canceren
dc.identifier.issn0959-8049-
dc.identifier.pmid1782072-
dc.identifier.urihttp://hdl.handle.net/10541/108782-
dc.description.abstractA region-specific radioimmunoassay has been employed to measure levels of immunoreactive parathyroid hormone-related protein(50-69) (iPTHrP(50-69)) in patients with tumour-induced hypercalcaemia (TIH). This assay is based on an antiserum raised against synthetic human PTHrP(50-69). The assay showed no cross-reactivity with human or bovine parathyroid hormone(1-84). The effect of a single dose (60 mg) of pamidronate was studied in 25 consecutive patients with TIH. All were rehydrated prior to treatment. All but 2 patients (8%) became normocalcaemic after treatment; both of these had very high levels of iPTHrP(50-69). Time to achieve normocalcaemia, as an index of relative resistance to pamidronate, correlated positively with pretreatment level of iPTHrP(50-69). Absence of radiological evidence of bone metastases also predicted relative resistance to pamidronate. In this study, iPTHrP(50-69)-induced osteoclastic bone resorption was a more important mechanism in the causation of TIH than PTHrP-induced renal reabsorption of calcium as assessed by the renal thresholds for calcium and phosphate.en
dc.language.isoenen
dc.subjectBone Canceren
dc.subjectBreast Canceren
dc.subjectLung Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshBone Neoplasms-
dc.subject.meshBreast Neoplasms-
dc.subject.meshDiphosphonates-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshHypercalcemia-
dc.subject.meshLung Neoplasms-
dc.subject.meshLymphoma, Non-Hodgkin-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshParathyroid Hormone-
dc.subject.meshParathyroid Hormone-Related Protein-
dc.subject.meshProteins-
dc.titleParathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital, Manchester, U.K.en
dc.identifier.journalEuropean Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.